Get the Stockscreener App
5.61
0.00%
0.00
After Hours:
5.61
Cytek Biosciences Inc stock is traded at $5.61, with a volume of 727.60K.
It is up +0.00% in the last 24 hours and down -17.38% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$5.61
Open:
$5.66
24h Volume:
727.60K
Relative Volume:
0.98
Market Cap:
$722.63M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-62.33
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
-0.88%
1M Performance:
-17.38%
6M Performance:
-0.18%
1Y Performance:
-29.35%
1-Day Range:
$5.51
$5.68
1-Week Range:
$4.90
$5.68
52-Week Range:
$4.66
$9.3283
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
5.61 | 722.63M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Strategic Investor Access: Cytek Sets Ambitious 4-Conference Roadshow for Early 2025 - StockTitan
Cytek Biosciences (NASDAQ:CTKB) Shares Down 4%Here's What Happened - MarketBeat
Pacer Advisors Inc. Buys Shares of 30,155 Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4% – Should You Sell? - Armenian Reporter
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 4.66, Closing at 5.39 - The Dwinnex
Cytek Biosciences (NASDAQ:CTKB) Trading Up 5%Here's What Happened - MarketBeat
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs - MSN
Cytek Biosciences (NASDAQ:CTKB) Cut to Sell at The Goldman Sachs Group - Defense World
Cytek Biosciences (NASDAQ:CTKB) Shares Down 5.5%What's Next? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownWhat's Next? - MarketBeat
The Goldman Sachs Group Downgrades Cytek Biosciences (NASDAQ:CTKB) to Sell - MarketBeat
(CTKB) Trading Report - news.stocktradersdaily.com
Cytek cut from buy to sell by Goldman Sachs (CTKB:NASDAQ) - Seeking Alpha
Goldman Sachs cuts Cytek Biosciences stock rating to sell - MSN
Goldman Sachs Downgrades Cytek Biosciences to Sell From Buy, Adjusts Price Target to $4.50 From $7 - Marketscreener.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Institutional investors may adopt severe steps after Cytek Biosciences, Inc.'s (NASDAQ:CTKB) latest 24% drop adds to a year losses - Simply Wall St
JPMorgan Chase & Co. Lowers Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Preliminary Full Year 2024 Revenue Results AnnouncedOn January 15, 2025, Cytek Biosciences, Inc. released its preliminary unaudited revenue for the fourth quarter and full year that concluded on December 31, 2024. T - Defense World
Cytek Biosciences expects FY24 revenue to be between $200M and $201M - MSN
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results - GlobeNewswire
Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
Cytek Biosciences shares take a hit after Q4 sales miss estimates By Investing.com - Investing.com South Africa
Cytek Biosciences shares take a hit after Q4 sales miss estimates - Investing.com Canada
Cytek Biosciences reports 4% annual revenue growth By Investing.com - Investing.com Australia
Cytek Biosciences Shares Fall On Low Preliminary 4Q Revenue - MarketWatch
Cytek Biosciences reports 4% annual revenue growth - Investing.com
Cytek Biosciences Projects 4% Revenue Growth to $201M for 2024, Mixed Q4 Performance - StockTitan
GAMMA Investing LLC Acquires 3,635 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Barclays PLC Increases Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - MarketBeat
Barclays PLC Has $1.12 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Stock Price Up 5.9%What's Next? - MarketBeat
Upgrading Cytek Biosciences Stock On An Upcoming Catalyst (NASDAQ:CTKB) - Seeking Alpha
Principal Financial Group Inc. Has $2.79 Million Stock Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Jane Street Group LLC Has $756,000 Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Cytek Biosciences to Present at J.P. Morgan Healthcare Conference 2024: Key Investor Event - StockTitan
76,117 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Acquired by Franklin Resources Inc. - Defense World
(CTKB) Technical Data - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Down 6.6% in December - MarketBeat
Stock Buyback Program Announced by Cytek Biosciences (NASDAQ:CTKB) Board of Directors - Defense World
Cytek Biosciences (NASDAQ:CTKB) to Buyback $50.00 million in Stock - MarketBeat
Cytek Biosciences, Inc. authorizes a Buyback Plan. - Marketscreener.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Acquired by Barclays PLC - Defense World
Crude Oil Gains 1%; Chicago PMI Falls In December - Benzinga
Cytek Biosciences (NASDAQ:CTKB) Trading 5.9% HigherWhat's Next? - MarketBeat
Cytek Biosciences stock jumps on new $50M buyback plan By Investing.com - Investing.com Nigeria
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025 - GlobeNewswire
Cytek Biosciences Announces New $50 Million Share Buyback Program for 2025 - StockTitan
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):